济民药业,关爱无限 www.pidrug.com
香港济民药业微信二维码
198 9654 1773
当前位置:首页 > 药品资讯 > 精神科 > 氧异安定Clobazam(氯巴占)

氧异安定Clobazam(氯巴占)

[ 人气:139 | 日期: 2020-08-04 | 返回 | 打印 ]
氧异安定Clobazam(氯巴占)
药品名称:氧异安定Clobazam(氯巴占)
药品别名:氯巴扎姆、氯巴扎母、氯巴扎酮、氧异安定、异安定酮
英 文 名:Clobazam
药品价格:$ 美国市场售价 102.65 美元
研发公司:
适 用 症:适用于治疗对其它抗癫痫药无效的难治性癫痫
型号规格:10mg/20mg两种规格,每瓶100片装。
药品详情:

【氧异安定Clobazam(氯巴占) 简述】
 
    氧异安定,别名氯巴扎姆、氯巴扎母、氯巴扎酮、氧异安定、异安定酮,英文名Clobazam,属于一类精神类药品。


氧异安定Clobazam(氯巴占)_香港济民药业

氧异安定Clobazam(氯巴占)_香港济民药业
 
【氧异安定Clobazam(氯巴占) 适应症】
 
    氧异安定Clobazam(氯巴占)适用于治疗对其它抗癫痫药无效的难治性癫痫,可单独应用,亦可作为辅助治疗用。对复杂部分性发作继发全身性发作和 Lennox-Gas-laut综合征效果更佳。
 
【氧异安定Clobazam(氯巴占) 规格】
 
    本品为片剂,分为10mg/20mg两种规格,每瓶100片装。
 
【氧异安定Clobazam(氯巴占) 服用方法】
 
    口服:从小剂量开始,每日 20— 30mg(0.5— 1mg/kg),逐步加量。如与其它抗癫痫药合用,则应减少本品剂量,每日应用 5— 15mg(0.1— 0.3mg/kg)。
 
  如连续应用,其抗惊厥作用逐渐减弱,可采用“放假疗法”,如女性患者,在月经期发作时,可在月经来潮前 2—3天开始用药,10天后停用。
 
【氧异安定Clobazam(氯巴占) 注意事项】
 
    本品具有抗焦虑和抗惊厥作用,抗电休克作用的ED50比地西泮小而比苯巴比妥、丙戊酸钠大。治疗安全范围比地西泮、苯巴比妥、丙戊酸钠宽。口服吸收快而完全,服药 1— 3小时后达血药峰浓度,经肝脏代谢,代谢产物为 N-去甲基氧异安定,同样有抗惊厥作用,作用强度为氯巴占的 2/3。 t1/2为 60小时,如每日用药 30mg,约 6天达稳态血浓度。
 
【氧异安定Clobazam(氯巴占) 不良反应】
 
    偶见有轻度的镇静、焦躁、抑郁和肌无力。
 
【氧异安定Clobazam(氯巴占) 生产厂家】
 
    氧异安定Clobazam(氯巴占)由美国新泽西伊顿敦的子公司West-ward生产。
 
Clobazam

 
Clobazam (marketed under the brand names Frisium, Urbanol, Onfi and Tapclob ) is a benzodiazepine class medication that was patented in 1968[1] and has been marketed as an anxiolytic since 1975[2] and an anticonvulsant since 1984.[3]
 
Medical uses
 
Clobazam is used for epilepsy. It is unclear if there are any benefits to clobazam over other seizure medications for children with Rolandic epilepsy or other epileptic syndromes.[4][needs update]
 
As of 2005, clobazam is approved in Canada for add-on use in tonic-clonic, complex partial, and myoclonic seizures.[5] Clobazam is approved for adjunctive therapy in complex partial seizures[6] certain types of status epilepticus, specifically the myoclonic, myoclonic-absent, simple partial, complex partial, and tonic varieties,[7] and non-status absence seizures. It is also approved for treatment of anxiety. In India, clobazam is approved for use as an adjunctive therapy in epilepsy and in acute and chronic anxiety.[8] In Japan, clobazam is approved for adjunctive therapy in treatment-resistant epilepsy featuring complex partial seizures.[9] In New Zealand, clobazam is marketed as Frisium[10] In the United Kingdom clobazam (Frisium) is approved for short-term (2–4 weeks) relief of acute anxiety in patients who have not responded to other drugs, with or without insomnia and without uncontrolled clinical depression.[11] It was not approved in the US until October 25, 2011, when it was approved for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age or older.[12]
 
It is also approved for adjunctive therapy for epilepsy in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. It is not recommended for use in children between the ages of six months and three years, unless there is a compelling need.[11] In addition to epilepsy and severe anxiety, clobazam is also approved as a short-term (2–4 weeks) adjunctive agent in schizophrenia and other psychotic disorders to manage anxiety or agitation.[11]
 
Clobazam is also available as an oral suspension in the UK, under the trade name of Tapclob.
 
Clobazam is sometimes used for refractory epilepsies. However, long-term prophylactic treatment of epilepsy has considerable drawbacks, most importantly loss of antiepileptic effects due to tolerance which may render long-term therapy ineffective.[13] Other antiepileptic drugs may therefore be preferred for the long-term management of epilepsy. Furthermore, benzodiazepines have the drawback, particularly after long-term use, of causing rebound seizures upon abrupt or over-rapid discontinuation of therapy forming part of the benzodiazepine withdrawal syndrome.
 
Contraindications
 
Clobazam should be used with great care in patients with the following disorders:
  Myasthenia gravis
  Sleep apnea
  Severe liver diseases such as cirrhosis and hepatitis[14]
  Severe Respiratory Insufficiency
Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.[15]
 
Overdose
 
Overdose and intoxication with benzodiazepines, including clobazam, may lead to CNS depression, associated with drowsiness, confusion, and lethargy, possibly progressing to ataxia, respiratory depression, hypotension and rarely coma or death. The risk of a fatal outcome is increased in cases of combined poisoning with other CNS depressants, including alcohol.[18]
 
 




注:药品如有新包装,以新包装为准。以上资讯仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。

更多相关资讯:返回顶部
最新药品资讯
  • Venclyxto(维奈妥拉)联合MabThera治疗慢淋白血病,患者死亡风险降低!
  • Tagrisso(Osimertinib)在英国获批用于两种肺癌适应症的治疗
  • ziritaxestat治疗弥漫性皮肤系统性硬化症(dcSSc)2期概念验证研究成功!
  • 美国FDA批准GSK三联疗法:可同时治疗哮喘和慢阻肺
  • NBIb-1817一次性治疗帕金森病(PD)显著改善运动功能、延长ON时间
  • 口服抗生素tebipenem HBr治疗cUTI和AP关键III期临床成功,疗效不劣于ertapenem
  • 下一代选择性免疫调节剂IMU-838治疗多发性硬化症(RRMS)具有显著疗效,有良好的安全性和耐受性!
  • Fintepla(芬氟拉明)口服溶液治疗Dravet综合征相关癫痫的第三项3期研究结果:抽搐发作显著减少
  • 视神经脊髓炎谱系障碍(NMOSD)创新药Enspryng(satralizumab)获美FDA批准
  • Fasenra与标准类固醇同时治疗鼻息肉三期临床结果积极
  • Darzalex Faspro申请新适应症,治疗轻链(AL)淀粉样变性!
  • 地诺单抗(Xgeva,denosumab)治疗实体瘤骨转移疗效怎样?
  • 新药IDH1抑制剂Tibsovo治疗胆管癌效果怎么样?
  • 拜耳Nubeqa(达罗他胺)治疗非转移性去势抵抗性前列腺癌显著延长患者生存!
  • FDA对罗氏Tecentriq治疗三阴性乳腺癌研究发出警告!
  • 加码多发性硬化症!罗氏启动三项临床试验研究
  • Xeglyze说明书-价格-功效与作用-副作用
  • 赛诺菲/再生元Dupixent(达必妥®)显著延缓哮喘患者肺功能下降:疗效维持3年!
  • 默沙东止咳药gefapixant2项关键III期临床试验成功:咳嗽频率显著降低
  • Ryplazim(纤溶酶原)再次申请上市:首个先天性纤溶酶原缺乏症(C-PLGD)治疗药物!
  • 拜耳Adempas用于经PDE5i治疗反应不足的肺动脉高压(PAH)患者IV期临床成功
  • Midostaurin(米哚妥林)适应症是什么?优势在哪里?
  • 艾普利Apixaban可以在哪里买到正品?
  • 维奈妥拉/维奈托克(VENETOCLAX)怎么服用?注意事项是什么?
  • 芦可替尼Ruxolitinib治疗特应性皮炎效果好不好?
  • 巯嘌呤片(6-MP)Puri-nethol治疗急性白血病效果如何?
  • 晚期HCC患者能从Ramucirumab中获益吗?
  • 赫赛汀+拉帕替尼治疗乳腺癌效果更好
  • 欧盟批准Imfinzi(英飞凡):一线治疗广泛期小细胞肺癌(ES-SCLC)!
  • 第三代强效COMT抑制剂Ongentys(opicapone)用于治疗帕金森病(PD)的新药在日本上市!


  • 如您发现本网站有文字编辑或内容错误,请点击此处发送(需要安装有foxmail或outlook支持),


    或发邮件至:info@morecare.hk,香港济民药业感谢您的到访!


    欢迎您添加香港济民药业微信,或在公众号内留言。

    香港济民微信公众号
    • 香港济民药业友情链接
    • 友情链接

    联系我们:

    地址:
    Rm. 314, Sun Ling Plaza, 30 On Kui Street, Fanling, HONG KONG
    邮箱:
    info@pidrug.com
    电话:
    198 9654 1773
    粤ICP备17150936号
    香港济民药业官方网站
    • 关注我们 :
    • 香港济民药业微博
    • 关注香港济民药业博客
    • 香港济民药业微信公众号